Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

High-yield bargain opportunities exist for disciplined, value-focused investors. Read more about the two standout stocks I've ...

The biotech industry can be volatile even for relatively large companies. Amgen (NASDAQ: AMGN), one of the more prominent ...

Next-generation sequencing allows for critical insights into gene therapy products, which can help streamline and accelerate ...

LSU football was handed a gut-wrenching loss in Week 11 by No. 11 Alabama, a loss that significantly impacted its College Football Playoff odds and path. Already dealing with a small room for ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Flashes of Navy and Gold ran all over Florida State football as Notre Dame handed the Seminoles a 52-3 loss Saturday night. In front of a nearly sold-out Notre Dame Stadium, the Fighting Irish (8 ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...

They've been dubbed 'game-changers' in the world of obesity, making the seemingly impossible, possible - significant weight ...

Put differently, at least one patient in the MariTide program experienced a loss of bone density. Such a loss could ...